---
document_datetime: 2025-11-25 10:41:59
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/herceptin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: herceptin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 8.4900746
conversion_datetime: 2025-12-22 20:06:02.828179
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Herceptin

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber   | Scope                       | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|-----------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVECHANGES-A.7 | 24/11/2025                          |                                          | Annex II                        |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000313845                     | Deletion of manufacturing sitesfor an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place,orsupplierof astartingmaterial, reagent or excipient (when mentioned in the dossier)*- Accepted                                                                                                                                                                                                                                                        |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000287554 | This was an applicationfor avariation following a worksharing procedure according toArticle 20 of CommissionRegulation(EC) No 1234/2008. B.I.a.1 Change in themanufacturer of a starting material/reagent/intermediate used in themanufacturingprocess of the active substanceorchangeinthemanufacturer (including where relevant quality control testing sites)ofthe active substance,where noPh.Eur.Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage siteofMaster Cell Bank and/orWorkingCell Banks -Accepted | 13/11/2025 | N/A |
| Variation type IB / EMA/VR/0000300702 | B.I.a.4 Change toin-process tests orlimits applied during the manufacture of the active substance-B.I.a.4.cDeletion of a non- significant in-process test - Accepted B.IACTIVESUBSTANCE-B.I.zOther variation - Accepted                                                                                                                                                                                                                                                                                                                           | 28/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Variation type IB / EMA/VR/0000295324   | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS - C.I.z Implementation of QRD template -Accepted C.I.z. - to update the SmPC and Package Leaflet in line with theInformationfor the packageleaflet regarding polysorbates used as excipients in medicinal products for human use and Excipients in the labelling andpackageleafletofmedicinalproductsfor humanuse.TheMAHhastakenthe opportunity to make minor editorial changes in linewiththeQRDtemplateaswell as editorialchangesthroughoutthewhole ProductInformation.In addition,section 6 of the Package Leaflet was updated and the followinglocalrepresentativehavebeen merged: Belgium and Luxembourg, Cyprus and Greece,Ireland and Malta'.The refence to the 'United Kingdon (Northern Ireland)' hasbeenremovedasperWindsor frameworkandQRDtemplate.ThelocalEU Annexes have been updated accordingly as needed,inparticular,anerrorinsection4of thePLof theNL annexeswere alignedwith the EN.   | 17/10/2025   | SmPC, Annex II, Labelling and PL   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------------------------------|
| Variation type IA / EMA/VR/0000281267   | B.1.b.2 Change in test procedure for active substance or starting material/reagent/intermediateusedinthe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/06/2025   |                                    |

<div style=\"page-break-after: always\"></div>

|                                       | manufacturingprocessoftheactive substance -B.I.b.2.a Minor changes to an approved test procedure-Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |          |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|
| Variation type IA / EMA/VR/0000254616 | A. ADMINISTRATIVE CHANGES -A.4 Change in the name and/or address of:a manufacturer(includingwhererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureof the active substance (where specified in the technical dossier)wherenoPh.Eur.Certificateof Suitability is part of the approved dossier; or a manufacturer of a novel excipient(where specified in the technical dossier) - Accepted                                    | 29/04/2025 |     | Annex II |
| Variation typeIA/ EMA/VR/0000240448   | A.5 Change in the name and/or address of a manufacturer/importerofthefinished product (including batch release or quality control testing sites)-A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Refused A.ADMINISTRATIVECHANGES-A.4Change in the name and/or address of: a manufacturer(including whererelevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive | 21/01/2025 | N/A |          |

<div style=\"page-break-after: always\"></div>

| substance(where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturerof anovelexcipient(where specified in the technical dossier) - Refused   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|